Fig. 3: Pharmacogenomic variants associated with differential anticoagulant response.
From: Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
ABCB1 ATP-binding cassette sub-family B member 1, CES1 carboxylesterase 1, CYP2C9 cytochrome P450 2C9, CYP2C18 cytochrome P450 2C18, FCGR2A immunoglobulin G (IgG) receptor IIa gene, FPGS folylpolyglutamate synthase, HLA-DRA human leucocyte antigen class II, DR alpha, INR international normalised ratio, PTPRJ protein tyrosine phosphatase receptor type J (CD148), TDAG8 T-cell death-associated gene 8, VKORC1 vitamin K 2,3 epoxide reductase complex 1, WSD warfarin stable dose.
